The action of a gene called ATDC is required for the development of pancreatic cancer, a new study finds.
The work builds on the theory that many cancers arise when adult cells—to resupply cells lost to injury and inflammation—switch back into more “primitive,” high-growth cell types, like those that drive fetal development.
When this reversion happens in the presence of other genetic mistakes, a repair process meant to start and stop quickly continues unchecked.
New details of this cancer-causing switch to primitive cells, and of the role of ATDC in pancreatic cancer formation, are revealed in a study of mice and human patient samples published online May 2 in the journal Genes & Development.
Led by researchers from NYU School of Medicine and the University of Michigan—Ann Arbor, the study found that ATDC must be active if pancreatic cells, when injured, are to reacquire primitive stem-cell qualities and undergo the early steps that lead to the development of pancreatic cancer.
“We found that deleting the ATDC gene in pancreatic cells resulted in one of the most profound blocks of tumor formation ever observed in a well-known mice model engineered to develop pancreatic ductal adenocarcinoma, or PDA, which faithfully mimics the human disease,” says corresponding author Diane Simeone, MD, director of the Pancreatic Cancer Center of NYU Langone Health’s Perlmutter Cancer Center. “We thought the deletion would slow cancer growth, not completely prevent it.”
The search for better treatment in these cases is especially urgent, says Dr. Simeone, given that PDA has the worst prognosis of any major malignancy and is on track to become the second leading cause of cancer-related death by 2030.
Healing Gone Awry
The study focused on acinar cells in the pancreas that secrete digestive enzymes through a network of partnering ducts into the small intestine. These same digestive enzymes can subject this tissue to low levels of damage. In response, acinar cells have evolved to readily switch back into stem cell types that resemble their high-growth ancestors, a feature that they share with pancreatic duct cells.
This ability to regenerate comes at a price, researchers say, because such cells are prone to become cancerous when they also acquire random DNA changes, including those in the gene KRAS that are known to drive aggressive growth in more than 90 percent of pancreatic cancers.
Specifically, stressed acinar cells are known to temporarily undergo acinar-to-ductal metaplasia, or ADM, a step toward a primitive cell type, to resupply cells. This sets the stage for a second shift into pancreatic intraepithelial neoplasia, or PanIN, in which cells no longer multiply under normal controls.
In the current study, the researchers found that mutant KRAS and other genetic abnormalities induced aggressive pancreatic cancer in 100 percent of study mice when the ATDC gene was present and active, but in none of the same cancer-prone mice lacking the gene. Neither did acinar cells in the ATDC “knock-out” mice undergo ADM or transformation to PanIN.
To get a better look at the early steps in pancreatic cancer formation, the research team artificially caused pancreatitis in mice by treating them with cerulein, a signaling protein fragment that damages pancreatic tissue. ATDC gene expression did not increase right after the damage, but did so a few days later and in line with the timeframe required for acinar cells to reprogram genetically into their ductal cell forebears.
Further experiments confirmed that the expression of ATDC triggers beta-catenin, a cell-signaling protein that, upon receiving the right trigger, activates genes including SOX9. Earlier studies linked SOX9 to the development of ductal stem cells and to the aggressive growth seen in PDA. Consistent with this work, the current study found that the inability of cells lacking ATDCto become cancerous was due to their inability to induce SOX9 expression.
The authors also examined ATDC expression in ADM lesions from 12 samples of human pancreatic tissue. The team found it to be more active in human ADM lesions along with beta-catenin and SOX9, and its activation increased further during the transition of ADM into human pancreatic ductal adenocarcinoma.
The findings, says Dr. Simeone, identify ATDC, beta-catenin, SOX9, and their signaling partners as potential targets in the design of new treatment approaches and prevention strategies for pancreatic cancer.
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Canceron October 7, 2020 at 5:04 am
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today ...
- NantKwest/ImmunityBio expand mid-stage pancreatic cancer studyon October 6, 2020 at 6:27 pm
NantKwest (NASDAQ:NK) and its collaborating partner ImmunityBio have announced to add a third cohort to ongoing Phase 2 immunotherapy trial for locally advanced or metastatic pancreatic cancer, and ...
- Yale cancer receives ACGT grant to advance strategies for treating pancreatic canceron October 6, 2020 at 6:40 am
Alliance for Cancer Gene Therapy (ACGT) gives $500,000 research grant to Sidi Chen, Ph.D., with Yale School of Medicine and Yale Cancer Center to advance strategies for treating pancreatic cancer ...
- Ruth Bader Ginsburg case highlights importance of early diagnosis for pancreatic canceron October 6, 2020 at 5:36 am
The recent death of Supreme Court Justice Ruth Bader Ginsburg is bringing more awareness to pancreatic cancer — the third leading cause of cancer deaths in the United States. Ginsburg's 11-year ...
- Hall of Famer, Cardinals legend Bob Gibson dies at 84 after battle with pancreatic canceron October 2, 2020 at 8:32 pm
Gibson becomes the second Cardinals Hall of Famer to die in the last month along with Lou Brock who died September 6.
- LI's pancreatic cancer walk goes virtual during pandemicon October 1, 2020 at 1:31 pm
When the 20th Long Island Walk for Pancreatic Cancer Research steps off this weekend, a very special survivor will be leading the way virtually. Joel Evans, 72, a Commack resident who is a five-year p ...
- Nonprofit Raises $1 Million for Pancreatic Cancer Researchon September 30, 2020 at 5:38 am
Sept. 20, nonprofit Purple Pansies received more than $1 million in donations to help end pancreatic cancer in their ...
- Competitive Scenario of Pancreatic Cancer Treatment Drugs Market Growth, Size, Demand, Forecast with Depth Assessment by Top Key Players 2025on September 29, 2020 at 11:58 pm
Global ""Pancreatic Cancer Treatment Drugs Market""(2020-2026) status and position of worldwide and key regions, ...
- Hackensack Meridian CDI Scientists Find One-Two Punch Working Against Stubborn Pancreatic Cancer in Preclinical Modelson September 29, 2020 at 6:50 am
PRNewswire/ -- A one-two punch of changing gene expression, then deploying immune checkpoint inhibitors, shows promise in battling one of the most treatment-resistant types of ...
- What coverage does Medicare provide for pancreatic cancer?on September 29, 2020 at 4:53 am
Medicare covers many treatments and services related to pancreatic cancer. Out-of-pocket costs may apply. Read on for more information.
via Bing News